| Not Yet Recruiting | "Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC COVID-19 | Phase 1 | 2025-09-01 |
| Not Yet Recruiting | Clinical Study of the Safety and Pharmacokinetics of the Drug Fluorothiazinone, a Concentrate for Solution Pre Safety and Pharmacokinetics | Phase 1 | 2025-09-01 |
| Not Yet Recruiting | An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Partic P. Aeruginosa, Baumannii, Klebsiella Pneumonia | Phase 3 | 2025-02-17 |
| Not Yet Recruiting | Study of the Drug B11-FC (Botulism Treatment) Botulism | Phase 1 / Phase 2 | 2024-08-01 |
| Recruiting | Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of No Gram Negative Pneumonia, Gram-Negative Bacterial Infections, Bacteremia Caused by Gram-Negative Bacteria | Phase 2 | 2023-11-06 |
| Unknown | An Open-label Study of the Safety and Pharmacokinetics of the TGKP Acute Respiratory Distress Syndrome (ARDS) | Phase 1 | 2023-11-01 |
| Unknown | Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition) COVID-19 | Phase 3 | 2023-10-01 |
| Unknown | Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Par COVID-19 | Phase 3 | 2023-10-01 |
| Unknown | Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition. COVID-19 | Phase 3 | 2023-09-01 |
| Recruiting | The Surveillance Clinical Study of Rickettsiosis Rickettsiosis | — | 2023-04-01 |
| Unknown | Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 COVID-19 | Phase 2 | 2023-03-01 |
| Unknown | HIV A6 Genome In ART Unsuccessful Patients On DOR Virus-HIV | — | 2022-05-01 |
| Unknown | Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 1 / Phase 2 | 2022-03-08 |
| Unknown | Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac Tuberculosis | Phase 3 | 2022-01-20 |
| Unknown | Study of Gam-COVID-Vac in Adolescents Covid19, Vaccine Preventable Disease | Phase 2 / Phase 3 | 2021-07-05 |
| Unknown | Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light COVID-19 Prevention | Phase 3 | 2021-02-19 |
| Unknown | An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease Ebola Virus Disease | Phase 1 | 2021-02-15 |
| Unknown | An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine COVID-19 Prevention | Phase 1 / Phase 2 | 2021-01-15 |
| Unknown | A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in t Covid19, SARS-CoV Infection | Phase 3 | 2020-12-01 |
| Unknown | Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Ve Covid19 | Phase 3 | 2020-11-01 |
| Unknown | The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older Coronavirus Infection | Phase 2 | 2020-10-22 |
| Unknown | Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus Covid19 | Phase 3 | 2020-09-28 |
| Unknown | Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 Covid19 Prevention | Phase 3 | 2020-09-07 |
| Completed | An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID Preventive Immunization COVID-19 | Phase 1 / Phase 2 | 2020-06-17 |
| Completed | An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19 Preventive Immunization COVID-19 | Phase 1 / Phase 2 | 2020-06-17 |
| Unknown | Study of Safety and Immunogenicity of BVRS-GamVac MERS (Middle East Respiratory Syndrome), MERS | Phase 1 / Phase 2 | 2019-11-07 |
| Unknown | Study of Safety and Immunogenicity of BVRS-GamVac-Combi MERS (Middle East Respiratory Syndrome), MERS | Phase 1 / Phase 2 | 2019-11-06 |
| Completed | A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of t Healthy Volunteers | Phase 2 | 2019-10-18 |
| Unknown | A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Whooping Cough | Phase 1 / Phase 2 | 2019-06-04 |
| Completed | Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac Healthy | Phase 2 | 2018-12-01 |
| Completed | Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infectio Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa, Pseudomonas Infections | Phase 2 | 2018-10-17 |
| Completed | The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Influenza A Virus Infection, Influenza A, Influenza Epidemic | Phase 1 | 2018-10-15 |
| Completed | An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola Healthy | Phase 1 | 2018-03-12 |
| Completed | A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo Healthy Volunteers | Phase 1 / Phase 2 | 2017-11-03 |
| Completed | An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or Healthy Volunteer | Phase 1 | 2017-08-10 |
| Completed | International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Ebola Virus Disease, Prevention | Phase 4 | 2017-08-03 |
| Completed | A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Whooping Cough | Phase 1 | 2017-06-13 |
| Completed | Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine "GamTBvac" Against the Tubercul Tuberculosis | Phase 1 | 2017-01-15 |
| Completed | Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi Ebola Hemorrhagic Fever | — | 2016-10-01 |
| Completed | Open Study of the Duration of Immunity After Vaccination With GamEvac Hemorrhagic Fever, Ebola | — | 2016-10-01 |